Bordeaux_ESPN
Bordaeux_ESPN_Mobile

Primary Hyperoxaluria Type 1 (PH1)

European Society for Paediatric Nephrology (ESPN) 2026

Congress Details

calanderSeptember 30-October 3, 2026

locationBordeaux, France

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Oral

Agenda

02 October, 2026

Concordance-of-Baseline-Characteristics-and-Long-Term-Outcomes-With-Lumasiran-in-Pediatric-Patients-With-Primary-Hyperoxaluria-Type-1
icon Presentation Type
Oral Presentation
time icon Time
09:50 - 10:40 CEST
location icon Location
Focused Oral Communications – Chronic Kidney Disease 3 Hall E1 & E2
icon Title
Concordance of Baseline Characteristics and Long-Term Outcomes With Lumasiran in Pediatric Patients With Primary Hyperoxaluria Type 1: Real-World and Clinical Trial Evidence
mic Presenter

Efrat Ben-Shalom

Shaare Zedek Medical Center
Israel

03 October, 2026

Long-Term-Lumasiran-Treatment-and-Nephrocalcinosis-Outcomes-in-Primary-Hyperoxaluria-Type-1-A-Post-Hoc-Analysis-of-ILLUMINATE-B
icon Presentation Type
Oral Presentation
time icon Time
09:40 - 11:00 CEST
location icon Location
Spotlights on Genetic Kidney Diseases Hall E1 & E2
icon Title
Long-Term Lumasiran Treatment and Nephrocalcinosis Outcomes in Primary Hyperoxaluria Type 1: A Post Hoc Analysis of ILLUMINATE-B
mic Presenter

Wesley Hayes

Great Ormond Street Hospital for Children
France

Long-Term-Lumasiran-Treatment-in-Primary-Hyperoxaluria-Type-1-and-Advanced-Kidney-Disease-With-Final-60-Month-ILLUMINATE-C-Results-and-Pediatric-Isolated-Kidney-Transplant-Outcomes
icon Presentation Type
Oral Presentation
time icon Time
11:30 - 12:50 CEST
location icon Location
Breakthroughs in Pediatric Kidney Transplantation Hall E1 & E2
icon Title
Long Term Lumasiran Treatment in Primary Hyperoxaluria Type 1 and Advanced Kidney Disease With Final 60 Month ILLUMINATE C Results and Pediatric Isolated Kidney Transplant Outcomes
mic Presenter

Yaacov Frishberg, MD

Shaare Zedek Medical Center
Israel

 

Related Materials

Primary Hyperoxaluria Type 1 (PH1)

Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1

New England Journal of Medicine

Author(s)

Sander F Garrelfs, Yaacov Frishberg, Sally A Hulton, et al

April 2021

Primary Hyperoxaluria Type 1 (PH1)

Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria

eLife

Author(s)

Tracy L McGregor, Karen A Hunt, Elaine Yee, et al

March 2020